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SUMMARY
The objective of this study was to describe a pseudo-outbreak of C. difficile in a hospital, following a change in the method used 
to detect the toxin.
In February 2002, there were two cases of CDAD and in March 7 occurred, coinciding with a change of the test (from detection 
of toxin A to toxin A/B). An outbreak was suspected. Active surveillance and education of staff were started. A CDAD case was 
defined as a patient with acute onset of diarrhea (≥ three episodes of liquid stools) and a positive stool test. They were classified as 
hospital or community-acquired. Stool samples were also collected for C. difficile culture and isolates were typed using AP-PCR.
From March 2002 through December 2003 there were 138 cases of CDAD: 70% were hospital-acquired and among the 30% 
with CDAD present on admission, most (81%) came directly from the community (50% had no history of hospitalization). Fifty-
two percent of hospital-acquired CDAD and 94% of cases on admission had already used antibiotics. The incidence of CDAD in 
hospitalized patients during surveillance was 3.3 per 1000 patient-admissions. The incidence of CDAD present on admission was 
6.1/1000 patients. Sixteen isolates were typed and presented 13 different profiles. 
In conclusion, the CDAD increase in our study occurred due to change in diagnostic methods and not due to an outbreak, as 
suspected initially. The incidence in hospitalized patients was much lower than in reported outbreaks. There were 13 molecular types 
suggesting that an outbreak did not occur. CDAD was largely community-acquired.
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INTRODUCTION
Clostridium difficile is the most frequent cause of hospital-acquired 
diarrhea18,20. More recently C. difficile associated disease has become 
more severe leading to more frequent complications such as toxic 
megacolon and is more refractory to treatment14. Since the early 2000s, 
a new hyper virulent strain, NAP1/BI/027, has been responsible for 
outbreaks in North America and Europe20,27,31. Its epidemiology in Brazil 
is unknown and there have been no reports of outbreaks with hyper 
virulent strains in this country3,30.
The objective of this study is to describe a pseudo-outbreak of C. 
difficile in a hospital, following a change in the method used to detect 
the toxin.
METHODS
Hospital Sírio Libanês is a private hospital in the city of São Paulo, 
Brazil. In 2002-3 it had 250 beds, divided between surgical and medical 
wards, two intensive care units (ICU), a semi-critical unit and an oncology 
unit. There was also a day-hospital, an emergency department and an 
outpatient clinic. Surgical and oncological patients were the majority.
Active surveillance for nosocomial infections was continuous in the 
ICU and oncology unit and was performed during four months, every 
year, in the other hospital areas (February, May, August and November). 
Until February 2002 the Infection Control Department did not perform 
active surveillance for C. difficile associated disease (CDAD); when 
CDAD was suspected by the attending physician, a stool EIA test for toxin 
A was requested. From March 2002 on, the hospital started to perform 
an EIA test for toxins A and/or B (Premier Toxin A and B, Meridian 
Bioscience, Cincinnati, USA).
In February 2002, there were two cases of CDAD, and in March 
seven cases were detected, which coincided with the new test. However, 
a potential outbreak was suspected and active surveillance was started in 
all units of the hospital, allied with education of the staff on prevention 
measures.
A case of CDAD was defined as a patient who presented an acute 
onset of diarrhea (three or more episodes of liquid stools) and a positive 
stool test for C. difficile toxin. Only the first episode was considered for 
each patient. CDAD cases were classified as:
- Hospital-acquired: if they occurred after 48 hours of hospitalization.
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- Present on admission: if CDAD was present at hospital admission 
or within the first 48 hours of hospitalization, even if the patient had been 
hospitalized elsewhere or had received healthcare on an outpatient basis.
Stool cultures for C. difficile: Stool samples positive for toxin were 
frozen at -20 oC to be submitted later to culturing for C. difficile. One 
mL of the sample was added to 2 mL of 70% alcohol and incubated for 
one hour at room temperature. The mixture was inoculated in 10 mL 
of thioglycolate broth and maintained at 37 oC for seven days. After 
this period, the sample was plated on blood agar and maintained under 
anaerobic conditions for 48h. If there was a pure culture, it was plated on 
Cycloserine Cefoxitin Fructose Agar (CCFA) under anaerobic conditions. 
Culturing in blood agar was also performed10. If growth on this selective 
medium occurred, one colony was inoculated in 10 mL of BHI for DNA 
extraction. If there was a mixed culture on the blood agar, colonies were 
re-inoculated in thioglycolate broth and the procedure was repeated. 
Antimicrobial susceptibility tests were not performed.
DNA extraction and molecular typing (genotyping) by arbitrary 
primed polymerase chain reaction (AP-PCR)
One colony from each culture was inoculated in 10 mL of BHI and 
grown for 48 h in anaerobic conditions. Then two mL were frozen at -70 oC 
and DNA extraction was carried out with the remaining 8 mL. Extractions 
of DNA were performed as described elsewhere9. For typing AP-PCR was 
used with the arbitrary primer oligonucleotide T7 (GTAATACGACTCA
CTATAG)4,8,11,24,25. The PCRs were prepared in PCR buffer (50 mM KCl, 
20 mM Tris-HCl, 2.5 mM MgCl2, 100 mg of bovine serum albumin per 
mL [pH 8.4]) containing 40 pmol of T-7, 1 mM of each deoxynucleoside 
triphosphate, 2 U Taq of DNA polymerase and one mg of DNA. The PCR 
profile was one step at 95 oC for five min, followed by twice at 95 oC for 
one min, 26 oC for one min and two min at 72 oC. After these two low 
stringency cycles, the arbitrary primer was heated at 95 oC for one min, 
50 oC for one min, and 72 oC for two min in the subsequent 55 cycles.
Identification of C. difficile was confirmed using primers for gene 16 
S rDNA11. Products of amplification were analyzed using electrophoresis 
in agarose gel and staining with ethidium bromide. Genotypes were 
defined on the basis of DNA banding patterns. Isolates with identical 
patterns were considered genotypically “indistinguishable”, while those 
that differed by one to four bands were subtypes of the same type and 
differing by five or more bands were considered distinct types26.
Outbreak control: All healthcare workers in the hospital were re-
trained in control measures, with emphasis on contact precautions and 
hand hygiene with chlorhexidine 2% soap and water. Alcohol based 
hand disinfection was discouraged in C. difficile patient rooms. Routine 
concurrent cleaning of the environment with organic chlorine (500 
ppm) was initiated in case patient rooms, all intensive care units and 
operating rooms. Post discharge disinfection of all patient rooms was 
also chlorine based. No cohorting was instituted since all the patients 
were in individual rooms.
RESULTS
From March 2002 through December 2003 there were 138 cases 
of CDAD. Among the 138 patients, 53% were male and the mean age 
was 64 years (range: 1-95); 70% of the cases were hospital-acquired, 
and among the 30% with CDAD present on admission, most (81%) had 
come directly from the community and 50% had no history of previous 
hospitalization. Fifty-two percent of the patients with hospital-acquired 
CDAD and 94% of cases present on admission had used antibiotics: 19% 
had used third-generation cephalosporins, 13% intravenous vancomycin, 
6% a carbapenem, and 35% had used other antibiotics. Twenty-seven 
percent had used more than one antibiotic simultaneously. No patients 
received oral vancomycin prior to the diagnosis of CDAD. 
The monthly distribution of CDAD cases can be seen in Figure 1. The 
incidence of hospital-acquired CDAD during this period was 7.9/1000 
patients in ICUs; 10.5/1000 in oncology patients; and 1.3 in the other 
hospital units (Table 1). The incidence of CDAD present on hospital 
admission was 6.1/1000 patients. 
Stools from all the 138 cases were cultured for C. difficile; however, 
growth only occurred in 16 samples. AP-PCR identified 13 different 
clonal profiles (Fig. 2). There were three pairs of isolates that were 
considered to present similar profiles; however, the isolates in pairs 
occurred 22 days, 2.3 months and 5.5 months apart. The results of 
molecular typing were only available in February 2004, when it became 
clear that this was a pseudo-outbreak. 
DISCUSSION
The increase in CDAD observed in our study occurred due to the 
change in diagnostic methods and not due to an outbreak as suspected 
initially. There have been no reports of CDAD outbreaks in our country; 
however, due to reported outbreaks with the particularly virulent strain 
ribotype 027 (NAP1/BI/027 or CD027) in Europe and North America15,28,29, 
the increase in cases in a Brazilian hospital was especially worrisome and 
led to this investigation. In a Brazilian study performed in Rio de Janeiro, 
with a small number of isolates, the ribotypes identified were 014 and 1061, 
and the ribotype 027 has not been described in the country.
The incidence of CDAD in hospitalized patients in our study during 
active surveillance was 3.3 per 1000 patient admissions. This incidence 
is much lower than that described in other studies, including one in 
Dublin (21/1000 admissions) during a CD027 outbreak5, but similar to 
that described in a Turkish hospital (2.2 per 1000 admissions) by active 
surveillance in a non-outbreak setting6. In Brazil, C. difficile was detected 
Fig. 1 - Number of cases of Clostridium difficile associated disease from February 2002 
through December 2003, in Hospital Sírio Libanês, São Paulo, Brazil. In March 2002, the 
diagnostic method used was changed from test for toxin A only, to test for toxins A and B. 
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in 5.5% of hospitalized children with acute diarrhea7 and in 4.2% in 
another study21 that can be considered high for situations that were not 
described as outbreaks.
The importance of detecting toxin B besides toxin A has been 
discussed. Initially, toxin A was reported to be responsible for the 
disease14. However, the role of toxin B has been reviewed and is 
considered important, or even essential for virulence19. The sudden 
high incidence of C. difficile diarrhea observed in our study was not 
due to a monoclonal outbreak, as initially suspected, but to an increase 
in diagnosis offered by the detection of toxin A and B, thus, it was a 
pseudo-outbreak.
The low yield of cultures is difficult to explain. It may be due to 
the long time between freezing of the stool samples and culturing, false 
positive toxin results, or even the limited experience of our microbiology 
laboratory with this pathogen. 
Many different typing methods have been used for C. difficile. 
For the early and rapid detection of outbreak situations, methods such 
as restriction enzyme analysis, arbitrary primed polymerase chain 
reaction (AP-PCR), and PCR ribotyping are commonly used. For long-
term epidemiologic studies, multilocus sequence typing, multilocus 
variable number of tandem repeats analysis, and amplified fragment 
length polymorphism are of interest16,17. AP-PCR was compared with 
immunoblotting and restriction endonuclease analysis, and presented 
similar results23. Arbitrarily primed PCR, that relies on the T7 
oligonucleotide, was used to identify different strains and was sensitive 
and accurate to type C. difficile2,24. Our use of AP-PCR was sufficiently 
discriminatory, as there were 13 profiles among 16 isolates, which was 
enough to conclude that an outbreak did not occur.
Although originally considered a nosocomial-acquired condition, 
CDAD was largely community-acquired in our investigation (30%). Only 
half of these community-acquired cases had been hospitalized previously, 
but most had used antibiotics. A recent study of community-acquired 
CDAD in the Netherlands demonstrated a prevalence of 1.5% among 
stool samples sent to reference laboratories by 195 general practitioners. 
Most patients had not been hospitalized within the previous year, but more 
than half had used antibiotics within the previous six months2. The cause 
for this presence in the community has been explained by the previous 
hospitalization of patients and the use of antibiotics22, but this does still 
not explain the occurrence in our patients without these risk factors. It is 
possible that the presence in the community of asymptomatic carriers of 
C. difficile originating in hospitals has increased the community spread 
of this agent, especially in patients with underlying conditions. 
This study has limitations. Only isolates from 16 of 138 cases (12%) 
were typed, but our results showed such a large variety of molecular types 
that it is highly unlikely that a clonal outbreak was missed. However, this 
low positive rate was a limitation of the study. We did not compare our 
isolates directly with the CD027 strain, but the relatively mild clinical 
presentation of our cases suggests that this was not a problem in our 
hospital. Although the data are relatively old and therefore may not 
represent what occurs currently, no changes in the clinical features of 
C. difficile associated disease have been observed in our hospital since 
the occurrence of the pseudo-outbreak, which suggests that, if present, 
very virulent strains such as CD027, or the more recently described 
CD0789, are not yet an important problem in our setting. However, the 
environmental control measures instituted during the pseudo-outbreak 
were kept in place until the present time.
RESUMO
Pseudo-surto de diarréia associada a Clostridium difficile (DACD) 
em hospital terciário
O objetivo deste estudo foi descrever um pseudo-surto de C. difficile 
em um hospital após a troca do método de detecção de toxina.
Table 1
Distribution of cases of Clostridium difficile associated disease (CDAD) and incidence of hospital-acquired cases, 
from March 2002 through December 2003, in Hospital Sírio Libanês, São Paulo, Brazil
Hospital Unit Number of cases 
present on admission
Number of hospital-
acquired cases
Total number 
of patients
Incidence of hospital-
acquired CDAD 
(per 1000 patients)
 Hospitalized patients ICU 4 51 6,456 7.9
Oncology 7 19 1,809 10.5
Other 26 26 20,000 1.3
Non hospitalized patients 5 0 826 -
Total 42 96 29,091 3.3
ICU: intensive care unit.
Fig. 2 - Molecular profiles obtained by arbitrary primed polymerase chain reaction of 16 
isolates of C. difficile cultured from the stool of patients with C. difficile associated disease 
from March 2002 through December 2003, in Hospital Sírio Libanês, São Paulo, Brazil.
Isolates 3 and 10 were considered to have a similar profile (collected 5.5 months apart), as 
well as isolates 11 and 16 (2.3 months apart) and isolates 8 and 12 (22 days apart). Lane 17 is 
the positive control; lane 18 is the negative control and L is a 100 bp molecular DNA marker.
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Em fevereiro de 2002 houve dois casos de DACD e em março 
ocorreram sete casos, que coincidiram com a mudança de teste (que 
detectava apenas toxina A e passou a detectar toxinas A e B). Foi 
suspeitado que houvesse um surto e vigilância ativa e reforço educacional 
para os profissionais de saúde foi implantado. Um caso de DACD foi 
definido como um paciente com início abrupto de diarréia (> 3 episódios 
de fezes líquidas) e um teste positivo. Os casos foram classificados como 
de aquisição comunitária ou hospitalar. Foram colhidas fezes para cultura 
para C. difficile e os isolados foram tipados por AP-PCR.
De março de 2002 a dezembro de 2003 houve 138 casos de DACD: 
70% foram hospitalares e, entre os 30% de casos comunitários, a maioria 
(81%) foi de pacientes provenientes diretamente da comunidade (50% 
não tinham histórico de internação). Cinquenta e dois por cento dos 
casos de DCAD hospitalar e 94% de casos na admissão haviam utilizado 
antimicrobianos. A incidência de DCAD em pacientes internados foi 
de 3,3/100 pacientes e na admissão foi 6,1/1000 pacientes. Dezesseis 
isolados foram tipados e apresentaram 13 perfis diferentes.
Em conclusão, o aumento de DACD no nosso estudo ocorreu por 
uma mudança de método diagnóstico e não devido a um surto como foi 
suspeitado inicialmente. A incidência em pacientes internados foi muito 
inferior ao que já foi relatado em surtos. Houve 13 perfis moleculares 
sugerindo que não ocorreu um surto. DACD foi, em grande parte, de 
aquisição comunitária.
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